Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Itolizumab by Equillium for Lupus Nephritis: Likelihood of Approval
Itolizumab is under clinical development by Equillium and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I...
Itolizumab by Equillium for Systemic Lupus Erythematosus: Likelihood of Approval
Itolizumab is under clinical development by Equillium and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Itolizumab by Equillium for Graft Versus Host Disease (GVHD): Likelihood of Approval
Itolizumab is under clinical development by Equillium and currently in Phase III for Graft Versus Host Disease (GVHD). According to...
Itolizumab by Biocon for Coronavirus Disease 2019 (COVID-19) Pneumonia: Likelihood of Approval
Itolizumab is under clinical development by Biocon and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to...
Itolizumab by Equillium for Systemic Lupus Erythematosus: Likelihood of Approval
Itolizumab is under clinical development by Equillium and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase...